No Data
No Data
Marumae, Trial ◆ Today's FISCO hot stocks ◆
Marumae <6264> announced a revision of its financial estimates for the fiscal year ending in August 2024. The revenue has been revised upwards from 4.68 billion yen to 4.749 billion yen, and the operating profit has been revised upwards from 0.077 billion yen to 0.155 billion yen. The revenue, which had expected approximately 0.15 billion yen in solar cell manufacturing equipment components in the other field, did not result in orders. On the other hand, orders for consumables expanded in the semiconductor field due to progress in inventory consolidation within customers. In addition, there was an upward revision due to an expansion in orders for G8 OLED in the FPD field. Trial.
The level at which it is easy to enter buying with the aim of waiting for pullbacks in TRIAL.
It was bought up to 3685 yen on September 4th, and then showed a correction, but has since fallen below the +1σ Bollinger Band. With the retreat of overheating, it is likely to be a level where dip-buying is easy to enter. In addition, on a weekly basis, it rose to +3σ and then adjusted, but now it is below +2σ, so the overheating has moderated.
Trial Holdings' August All Store Sales Rise 9%
Trial Holdings Inc. Sees Notable Sales Surge
Possibility of profit taking in the main stocks, with a battle of 600 points.
■The market is easily influenced by the external environment. This week's emerging markets, like the main board market, are likely to be easily influenced by the external environment. The US market at the end of the week fell sharply, and the exchange rate also moved higher, so there is a high probability that the Nikkei average at the beginning of the week will fall by about 1000 yen. Normally, a higher exchange rate is relatively positive for growth markets that have many domestic demand-oriented stocks, but in the midst of worsening investor sentiment, there is a low possibility of being seen as a buying factor. The main board that had been rising since the rebound from August 5.
Is it a nervous development, or is the US market being watched for the results of the FOMC?
Outlook for this week from September 9th to September 13th: Will the Tokyo Stock Exchange Growth ETF exhibit a nervous development, with a cautious focus on the US market awaiting the results of the FOMC? The market is likely to be easily influenced by external factors, similar to the main board market. Until the results announcement of the Federal Open Market Committee (FOMC) meeting on September 17-18, the focus will be on the US market. Stocks like Triral HD <141A> which had a good performance last week and GENDA <9166> trading near their all-time highs are likely to be sold.
No Data
No Data